Frequent somatic TET2 mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias
Authors:
- Thomas L. OlsonTOThomas L. Olson
- HeeJin CheonHCHeeJin Cheon
- Jeffrey C. XingJXJeffrey C. Xing
- Kristine C. OlsonKOKristine C. Olson
- Cait E. HameleCHCait E. Hamele
- Yaseswini NeelamrajuYNYaseswini Neelamraju
- Matt SchmachtenbergMSMatt Schmachtenberg
- Shriram K. SundararamanSSShriram K. Sundararaman
- Cheryl A. KellerCKCheryl A. Keller
Open Access
- 30 March 2021
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 138 (8) , 662-673
Abstract
Chronic natural killer large granular lymphocyte (NK-LGL) leukemia, also referred to as chronic lymphoproliferative disorder of NK cells, is a rare disorder defined by prolonged expansion of clonal NK cells. Similar prevalence of STAT3 mutations in chronic T-LGL and NK-LGL leukemia is suggestive of common pathogenesis. We undertook whole-genome sequencing to identify mutations unique to NK-LGL leukemia. The results were analyzed to develop a resequencing panel that was applied to 58 patients. Phosphatidylinositol 3-kinase pathway gene mutations (PIK3CD/PIK3AP1) and TNFAIP3 mutations were seen in 5% and 10% of patients, respectively. TET2 was exceptional in that mutations were present in 16 (28%) of 58 patient samples, with evidence that TET2 mutations can be dominant and exclusive to the NK compartment. Reduced-representation bisulfite sequencing revealed that methylation patterns were significantly altered in TET2 mutant samples. The promoter of TET2 and that of PTPRD, a negative regulator of STAT3, were found to be methylated in additional cohort samples, largely confined to the TET2 mutant group. Mutations in STAT3 were observed in 19 (33%) of 58 patient samples, 7 of which had concurrent TET2 mutations. Thrombocytopenia and resistance to immunosuppressive agents were uniquely observed in those patients with only TET2 mutation (Games-Howell post hoc test, P = .0074; Fisher’s exact test, P = .00466). Patients with STAT3 mutation, inclusive of those with TET2 comutation, had lower hematocrit, hemoglobin, and absolute neutrophil count compared with STAT3 wild-type patients (Welch’s t test, P ≤ .015). We present the discovery of TET2 mutations in chronic NK-LGL leukemia and evidence that it identifies a unique molecular subtype.Keywords
This publication has 58 references indexed in Scilit:
- Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activationBlood Cancer Journal, 2013
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samplesNature Biotechnology, 2013
- STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemiaBlood, 2012
- Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesisNature Genetics, 2012
- Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancerGenome Research, 2012
- Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2Nature, 2010
- TET2 mutations in childhood leukemiaLeukemia, 2010
- Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasmsJournal of Clinical Pathology, 2010
- Epitope mapping of HTLV envelope seroreactivity in LGL leukaemiaBritish Journal of Haematology, 1998